3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Hepatocellular
5
Leukemia, Myeloid, Acute
3
Uveal Melanoma
2
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
HER2 Negative Metastatic Breast Cancer
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Temozolomide
32
Radiotherapy
11
Bevacizumab
10
Surgical Procedures, Operative
7
IL13-PE38
7
TIC10 compound
6
Lomustine
6
Carboplatin
6
Radiation
5
Chlorotoxin
5
vorasidenib
4
trametinib
4
dabrafenib
4
Valacyclovir
4
OKN 007
4
Flucytosine
4
Dianhydrogalactitol
4
Cyclophosphamide
4
vocimagene amiretrorepvec
3
abemaciclib
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
CLR1404
3
trans-sodium crocetinate
2
pembrolizumab
2
olutasidenib
2
marizomib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled